Equities Analysts Set Expectations for Lantheus Q1 Earnings

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Lantheus in a research note issued on Tuesday, February 18th. Leerink Partnrs analyst R. Ruiz expects that the medical equipment provider will post earnings per share of $1.32 for the quarter. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share. Leerink Partnrs also issued estimates for Lantheus’ Q3 2025 earnings at $1.51 EPS, Q4 2025 earnings at $1.57 EPS and FY2025 earnings at $5.77 EPS.

LNTH has been the subject of a number of other research reports. The Goldman Sachs Group assumed coverage on Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company. Truist Financial reaffirmed a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Trading Down 3.2 %

LNTH opened at $78.23 on Thursday. The stock has a market cap of $5.44 billion, a price-to-earnings ratio of 13.02 and a beta of 0.44. Lantheus has a 1 year low of $56.44 and a 1 year high of $126.89. The stock has a fifty day moving average price of $90.31 and a 200 day moving average price of $97.06.

Hedge Funds Weigh In On Lantheus

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its stake in shares of Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock valued at $554,583,000 after purchasing an additional 2,610,118 shares during the period. Farallon Capital Management LLC grew its stake in shares of Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock valued at $475,590,000 after purchasing an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in shares of Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock valued at $135,025,000 after purchasing an additional 435,445 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Lantheus in the 4th quarter valued at approximately $36,183,000. Finally, Groupama Asset Managment bought a new stake in shares of Lantheus in the 3rd quarter valued at approximately $439,000. 99.06% of the stock is currently owned by institutional investors.

Insider Activity at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.